Put Options

31 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $11.7 Million - $15.3 Million
295,700 Added 46.04%
937,900 $48.5 Million
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $4.23 Million - $5.56 Million
105,000 Added 19.55%
642,200 $26.7 Million
Q1 2024

May 13, 2024

SELL
$47.98 - $54.4 $74.3 Million - $84.3 Million
-1,548,800 Reduced 74.25%
537,200 $29.1 Million
Q4 2023

Feb 09, 2024

BUY
$48.48 - $57.85 $9.01 Million - $10.7 Million
185,800 Added 9.78%
2,086,000 $107 Million
Q3 2023

Nov 09, 2023

BUY
$57.89 - $64.73 $13.8 Million - $15.4 Million
238,100 Added 14.33%
1,900,200 $110 Million
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $11.1 Million - $12.4 Million
-174,600 Reduced 9.51%
1,662,100 $106 Million
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $62.1 Million - $70.4 Million
-945,200 Reduced 33.98%
1,836,700 $127 Million
Q4 2022

Feb 08, 2023

BUY
$68.48 - $81.09 $64.6 Million - $76.5 Million
943,000 Added 51.28%
2,781,900 $200 Million
Q3 2022

Nov 10, 2022

BUY
$0.13 - $76.84 $22,334 - $13.2 Million
171,800 Added 10.31%
1,838,900 $131 Million
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $2 Million - $2.2 Million
27,500 Added 1.68%
1,667,100 $128 Million
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $6.85 Million - $8.21 Million
-111,400 Reduced 6.36%
1,639,600 $120 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $27.9 Million - $32.5 Million
519,802 Added 42.22%
1,751,000 $109 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $9.5 Million - $11.1 Million
-160,500 Reduced 11.53%
1,231,198 $72.9 Million
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $6.25 Million - $6.8 Million
100,900 Added 7.82%
1,391,698 $93 Million
Q1 2021

May 12, 2021

SELL
$59.34 - $66.74 $37 Million - $41.6 Million
-623,202 Reduced 32.56%
1,290,798 $81.5 Million
Q4 2020

Feb 11, 2021

BUY
$57.74 - $65.43 $43.6 Million - $49.4 Million
755,000 Added 65.14%
1,914,000 $119 Million
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $7.8 Million - $8.64 Million
135,800 Added 13.27%
1,159,000 $69.9 Million
Q2 2020

Jul 31, 2020

SELL
$54.82 - $64.09 $5.88 Million - $6.88 Million
-107,300 Reduced 9.49%
1,023,200 $60.2 Million
Q1 2020

May 01, 2020

SELL
$46.4 - $67.43 $35.4 Million - $51.5 Million
-763,921 Reduced 40.32%
1,130,500 $63 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $33 Million - $43.1 Million
671,021 Added 54.85%
1,894,421 $122 Million
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $12.2 Million - $14.5 Million
285,900 Added 30.5%
1,223,400 $62 Million
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $17.2 Million - $19 Million
385,800 Added 69.93%
937,500 $42.5 Million
Q1 2019

May 14, 2019

SELL
$45.12 - $53.8 $21.5 Million - $25.7 Million
-477,100 Reduced 46.37%
551,700 $26.3 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $653,384 - $847,282
-13,400 Reduced 1.29%
1,028,800 $53.5 Million
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $82,785 - $93,375
1,500 Added 0.14%
1,042,200 $64.7 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $19.8 Million - $24.7 Million
392,800 Added 60.63%
1,040,700 $57.6 Million
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $16.9 Million - $19.4 Million
-281,700 Reduced 30.3%
647,900 $41 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $12 Million - $13.1 Million
200,300 Added 27.46%
929,600 $57 Million
Q3 2017

Nov 14, 2017

SELL
$55.23 - $63.74 $17.5 Million - $20.1 Million
-316,100 Reduced 30.24%
729,300 $46.5 Million
Q2 2017

Aug 14, 2017

SELL
N/A
-245,300 Reduced 19.01%
1,045,400 $58.3 Million
Q1 2017

Nov 14, 2017

BUY
N/A
1,290,700
1,290,700 $70.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.